Costs of Grade 3 and 4 Adverse Events Associated with Current Cancer Treatments - Cost Estimations For Sweden, Norway, Finland And Denmark

Abstract

of prostate cancer patients with bone metastases (patients who were specifically coded as "Castration-resistant prostate cancer" (ICD-10, C61) and "8848040" (Japan MEDIS-DC)), who had been treated with ADT and a CRPC-targeted treatment (according to approved indication). Results: 276 patients were identified, with a mean age of 71.0 y.o (S.D. 8.7). Visceral metastasis was present in 43.8% of the patients, with the most common site being the lungs (34.4%). The mean treatment period for mCRPC was 34 months. 87.4% had undergone medical Androgen Deprivation Therapy (ADT), with 5.8% undergoing surgical ADT. Radiation therapy was given to 29.3% of patients, and 40% had been treated with opioids. 89.5% of the patients had undergone bone scanning. There were an average number of 67 outpatient visits and 2.8 inpatient admissions per patient during the treatment period. A mean of 9.9 laboratory and imaging examinations in the year prior to CRPC diagnosis was observed, increasing to a mean 28.6 one year post-diagnosis. The most common diagnostic and imaging combination done prior to mCRPC diagnosis was bone scintigraphy, CT, PSA, and blood biochemistry test. Mean per patient monthly costs increased 6-fold from prior to CRPC to post-CRPC diagnosis. ConClusions: Metastatic castration-resistant prostate cancer brings about increased resource use for patients in Japan, with a three-fold increase in diagnostic and monitoring tests, increased hospital visits, and increased monthly per patient costs as a result of diagnosis.